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Mutational spectrum and therapy response of metastasized GIST
in Central Switzerland - a population-based study
Abstract
Our data support previous observations, that PDGFRα mutations play no important role in metastasized
GISTs. The influence of Imatinib and Sunitinib therapy in metastasized GISTs with wild type genotype
and c-kit exon 9 mutations needs further investigation.
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Abstract 
Background: Until now, no population-based studies investigated the mutational status of 
primary GIST (PT) and corresponding metastases and correlated these data with response to 
Imatinib or Sunitinib therapy. 
Patients and methods: In a retrospective observation study, all metastatic GISTs of the last 15 
years of our institution were investigated for mutations in c-kit and in PDGFR gene in each 
PT and corresponding metastasis. Correlation with clinical outcome and response to Imatinib 
or Sunitinib therapy was performed. 
Results: In 13 PT c-kit mutations in exon 9 (3), exon 11 (7) and exon 13 (1), 2 wild type 
genotypes, and no PDGFR mutation were detected. In 3 metastases a switch from 
heterozygosity to homozygosity and one additional exon 13 mutation were observed. All 10 
persons with available follow-up received Imatinib as first-line chemotherapy. 5 of them (3 
exon 9 mutations, 1 wild type, 1 additional exon 13 mutation) stopped Imatinib due to tumour 
progression. In 3 cases, Sunitinib as second-line chemotherapy was ended due to same 
reasons. 
Conclusions: Our data support previous observations, that PDGFR mutations play no 
important role in metastasized GISTs. The influence of Imatinib and Sunitinib therapy in 
metastasized GISTs with wild type genotype and c-kit exon 9 mutations needs further 
investigations. 
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Introduction 
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of 
the gastrointestinal tract with an incidence of approximately 0.65 – 1.5 cases per 100’000 
inhibitants (1-6). The most frequently affected sites are stomach and small intestine, but 
GISTs may also develop in any other part of the GI tract, peritoneum and retroperitoneum. 
The finding, that approximately 95% of these tumours express CD117 (c-kit tyrosine kinase 
receptor) (7-8), has dramatically increased the diagnostic accuracy of these tumours. On a 
molecular level most GISTs harbour hyperactivating somatic mutations either in c-kit or 
PDGFR genes, occurring mostly in the juxtamembrane domains or in the extracellular 
region (9-10). This is the rationale for the treatment option with tyrosine kinase inhibitors like 
Imatinib (Gleevec®, Novartis, Switzerland) or Sunitinib (Sutent®, Pfizer, USA). The 
localisation of these mutations determines the efficiency of these substances, to inhibit the 
stimulatory effect of c-kit and PDGFR proteins on cell growth (11-12). 
In the last few years some unselected population-based studies from various European regions 
have been published, in which the mutational status of primary GISTs was investigated (2-6). 
In one of these studies, the genomic status of metastases was reported (2), but no correlation 
to the genomic status of corresponding primary tumour on the one hand and to the response 
after treatment with Imatinib and Sunitinib on the other hand was given. 
The aim of our study was to evaluate the status of c-kit and PDGFR mutations in 
metastasized GISTs of an unselected population in Central Switzerland, to describe the 
mutational spectrum of primary and corresponding metastatic tumours. In addition we 
correlated these results with the response to treatment with tyrosine kinase inhibitors Imatinib 
and Sunitinib. 
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Materials and methods 
Ethical considerations 
This was a retrospective study with no study-driven clinical intervention. No material was 
sent to external institutions. Approval of the local ethics committee was obtained (reference 
number EK 915). 
 
Retrieval of cases 
The record files of the Institute of Pathology of the Cantonal Hospital Lucerne were searched 
for all patients with GIST diagnosed in the period from 1995 – 2009. The search included all 
sites of the gastrointestinal tract as well as the intra-abdominal, mesenteric, omental, pelvic 
and retroperitoneal regions. In addition to GIST the search included all benign and malignant 
mesenchymal neoplasm as well as tumour-like conditions including fibromatosis, desmoids 
and inflammatory pseudotumour. The pathology reports and histological slides of patients 
with metastasized disease were re-evaluated (M.R.) and, in questionable cases, GIST 
diagnosis was confirmed by CD117 immunohistochemistry (see below). 
Since only metastasized tumours were investigated no risk stratification of malignancy or 
pathological staging of the GIST was performed. 
Clinical data including the treatment procedures (e.g. chemotherapy with Imatinib or 
Sunitinib, radiation, other therapies) after diagnosis of the primary and metastatic tumour, the 
response to therapy, and the state of disease at the end of the observation period were obtained 
from the treating oncologists. 
 
Immunohistochemical and molecular analysis 
Tissue probes of primary and metastatic tumours were fixed in 4% buffered formalin, 
embedded in paraffin and, after histopathological diagnosis, archived at the Institute of 
Pathology, Cantonal Hospital, Lucerne, Switzerland. All formalin- fixed paraffin-embedded 
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tumour blocks were reviewed (M.R.) for quality and tumour content, and a single 
representative tumour block from primary tumour and every available metastates of each case 
was selected for immunohistochemical and molecular analyses. 
Immunohistochemical reactions were performed with a Benchmark automatic 
immunostaining device (Ventana Medical System, Tucson, AZ, USA) according to the 
manufacturer’s instructions. Three-m thick tissue sections were incubated after heat induced 
antigen retrieval with antibodies against CD117 [clone A4502, DakoCytomation (Glostrup, 
Denmark), 1:50 dilution]. Positive and negative controls were included in each slide run. 
For molecular analysis, micro-dissection of selected areas of the representative tumour tissue 
blocks was performed. 
For molecular analysis of c-kit and PDGFR gene, DNA was extracted using the QIAamp 
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). PCR for c-kit exons 8, 9, 11-18 and 
PDGFR exons 10, 12, 14, 18 was performed in 20 l volumes using 50 ng of template 
DNA, 0.2 U HotstarTaq polymerase (Qiagen, Hilden, Germany), 2.5 mM MgCl2, 0.2 mM of 
dNTP (peqlab, Erlangen, Germany) and 400 nM of each primer (see Table 1). The cycling 
conditions were as follows: one cycle of 95°C 15 min; 50 cycles of 95°C 30 sec, 60°C 30 sec 
and 72°C 45 sec; one cycle of 72°C 5 min. The PCR products were purified with ExoSapIT 
(usb, Cleveland, Ohio). The sequencing reaction was carried out with BigDye Terminator Mix 
v 1.1 (Appplied Biosystems, Foster City, CA) according to the manufacture’s protocol. After 
cleaning the products with DyeEx (Qiagen) the probes were analysed using the abi 3130 
sequencing system (Applied Biosystems) and the Chromas software. Each sequencing 
reaction was performed at least twice starting from independent PCR reactions. Detected 
mutations were confirmed in the sequence as sense and antisense strands. Our results were 
compared with normal sequence available on gene ID 3815 (KIT) and gene ID 5156 
(PDGFR). 
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Results 
Of the 87 GIST (crude incidence rate: 0.97 per 100’000 inhabitants of Central Switzerland per 
year), diagnosed from 1995 to 2009 in our institution, 13 patients (14.9%) had metastatic 
disease, which equals a crude incidence rate of 0.14 per 100’000 inhabitants of Central 
Switzerland per year. All primary and all metastatic tumours showed a strong CD117 
expression. In three of the 13 metastatic cases, the metastases were diagnosed at the same 
time as the primary tumour. 
Patients and tumour characteristics are summarized in Table 2. The patients collective 
included 8 women (61.5%) and 5 men (38.5%), with a median age of 68 years (range 31 – 80) 
at the first GIST diagnosis. Primary tumours (PT) arose in stomach (6 cases; 46.2%), small 
intestine (4 cases; 30.8%), and 1 case each in pancreas, gastrocolic ligament, and rectovaginal 
septum. Metastases were found in the liver (6 cases, 33.3%), peritoneum, not otherwise 
specified (4 cases, 22.2%), omentum (3 cases, 16.7%), and retroperitoneum, mesenterium, 
rectovaginal septum, lymph nodes and bone (1 case each, 5.6%). 5 of the 13 patients (38.5%) 
had metastases in different organs (see Table 2). In 2 other patients with peritoneal metastases 
(patient A and C), tissue samples of 2 different, not otherwise specified peritoneal tumour 
sites were examined. 
Histologically 10 of 13 PT showed a spindle cell type (76.9%), 2 PT a mixed spindle cell / 
epitheloid type (15.4%), and one tumour of the small intestine an epitheloid type (7.7%). 
The median of the greatest diameter of PT was 9.5 cm (range 4 – 25 cm). Only 1 PT was less 
than 5 cm (7.7%), 6 PT ranged between 5 and 10 cm (46.2%), and 5 PT were greater than 10 
cm (38.5%). For one PT, confirmed by biopsy, no reliable tumour size was available. 
The mitotic count (per 50 high power fields (hpf)) ranged from 1 to 100 with a median of 8. 
The highest counts were observed in PT of the stomach (up to 100 mitoses per 50 hpf) and the 
small intestine (up to 40 mitoses per 50 hpf), whereas the extragastrointestinal PT showed a 
low mitotic count (range 1 to 6 mitoses per 50 hpf). 
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Molecular analyses could be performed in all PT and all above described corresponding 
metastases (see also Table 2). In patients with more than one metastatic site, the different 
metastases of the respective patient showed always the same genetic alterations. In 2 cases 
with PT in the stomach (patient C and H; 15.4%) no genetic alterations in the c-kit or in the 
PDGFR- genes could be detected neither in PT nor in metastases. The other 11 cases 
(84.6%) showed changes in the c-kit gene, but none in the PDGFR- gene. C-kit exon 9 
alterations could be detected in 2 PT of the small intestine and in the one PT of the pancreas. 
In all 3 cases the same well known duplication of codon 502-503 (p.502_503dup AY) was 
found in PT as well as in metastatic tumours in heterozygous form. Both PT and metastasis of 
the GIST of the septum rectovaginale showed a heterozygous exon 13 point mutation 
(p.K642E). The vast majority of PT (7 patients with PT in stomach, small intestine, and lig. 
gastrocolicum) showed heterozygous exon 11 alterations: One point mutation (p.W557G; case 
I), 5 deletions (p.W557_K558del in case D and J, p.K558_E562del in case G, 
p.E554_N567del in case K, and p.V559_G565del in case M), and 1 duplication 
(p.P577_R588dup12 in case L). In two of the cases (Patients J and L) metastatic tumours 
showed homozygosity for the same alteration as in the PT. In the metastatic tumour of patient 
D, two changes compared to the PT could be seen: Homozygosity of the exon 11 deletion and 
an additional heterozygous point mutation in exon 13 (p.V654A). Of the above mentioned 
genetic alterations, all but two have been previously described. The two exceptions are the 
exon 11 deletion (p.E554_N567del) of patient K and the exon 11 duplication 
(p.P577_R588dup12) of patient L. 
Full clinical data were available in 10 of 13 cases. In 2 patients metastatic GIST was initially 
diagnosed within the last 3 months of the study period, so no clinical data of the disease 
progression exist. One patient did not return for a follow-up after diagnosis of metastatic 
disease (25 months after PT diagnosis). The median observation period was 47 months (range 
1 – 180). The progression free survival after diagnosis of PT ranged from 6 to 114 months 
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(median 22 months). At the end of the follow-up period (January 15th 2010) 4 patients had 
died of disease, 3 patients had a stable disease, and 3 patients showed no evidence of disease. 
The range of overall survival after diagnosis of PT was 6 to 180 months (median 47 months) 
All 10 patients with appropriate clinical data received Imatinib as first-line tyrosine kinase 
inhibitor therapy during the observation period. Among these, the therapeutic regime varied 
considerably (see also Table 2): One patient (case C) received Imatinib as preoperative 
therapy (400mg/day for 1 month) of PT and then again after resection of metastatic tumour 
(800 mg/day). Another patient (case J) received Imatinib as postoperative therapy (400 
mg/day) of PT for 12 months and again after relapse of disease (400mg/day). The other 8 
patients received Imatinib after the radiological and/or histological diagnosis of metastases or 
local recurrency with an initial dose of 400 mg/day. So in 4 patients (C, D, H; J) the tissue 
probes of metastases used in this study were taken after the start of imatinib therapy and in six 
patients (A, B, E, F, G, I) before. 
In 1 case (patient A) a dose elevation to 600mg/day was performed after 38 months for 
another 25 months. In 2 other patients (E and F) the imatinib dosage was increased to 800 
mg/day after 20 month for 1 month and after 38 months for 3 months, respectively. The 
therapy was switched to Sunitinib in 5 patients (37.5 mg in 4 cases, 50 mg in one case, see 
also Table 2) due to tumour progression (3 patients), intolerance (1 patient) or a combination 
of both (1 patient) during imatinib application. The Sunitinib therapy in 3 of these 5 patients 
was stopped due to the same reasons (2 patients with intolerance, 1 patient with tumour 
progression). In patient E, Imatinib therapy was replaced by radiotherapy (30 Gy for 2 
weeks). In two patients, Imatinib therapy was terminated without substitution because of 
tumour progression (patient B) and side effects (patient H), respectively. 
In all 3 patients with alterations of the c-kit exon 9 a tumour progression was observed during 
Imatinib therapy, which was therefore stopped. Whereas 1 of the 2 remaining patients, in 
which the Imatinib therapy had to be ended due to tumour progression, showed no detectable 
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genetic alteration, the other one showed more genetic alterations in the metastasis compared 
to the PT: The heterozygous deletion in exon 11 of the c-kit gene of the PT changed to a 
homozygous deletion in metastasis and an additional point mutation in exon 13 of the c-kit 
gene was detected. 
Unfortunately, no clinical follow-up data exists for the two cases (patients K and L) that 
harbour the novel complex genetic alterations in exon 11 of the c-kit gene. 
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Discussion 
The present study is, to our knowledge, the first, which focuses on metastatic GIST in a 
population-based collective, analysing both the mutational status and response to tyrosine 
kinase inhibitor therapy. 
Our population data with a GIST crude incidence of 0.97 per 100’000 inhabitants per year and 
a proportion of 14% metastasized GIST is comparable to data reported by other groups (2-6). 
Compared to the study of Braconi and colleagues (2), which provides data of primary 
metastasized tumours of their whole GIST collective, the mutational status of our collective, 
included primary and secondary metastasized tumours, shows a slightly higher amount of 
wild type GIST (15.4% vs. 5%) and a similar proportion of c-kit mutations (84.6% vs. 90%). 
In contrast to their study (5%) we could not detect any PDGFR mutation. 
Also the site distribution of tumours (46.2% stomach, 30.8% small intestine, 24% other sites) 
is comparable to the data presented by Braconi et al. A difference could be observed in the 
histologic type of the tumours: While the vast majority of tumours in the present series 
showed a spindle cell type (76.9%) and only 15.4% and 7.7% a mixed or epitheloid type, 
respectively, more epitheloid (26%) and mixed type (31%) GISTs were reported in the 
metastatic group in their study. 
The genetic alterations of the investigated metastatic GIST’s are comparable to those, 
reported in literature for recurrent and metastasized GIST. The most frequently altered exon 
in the primary tumours of our study group was c-kit exon 11 (54%) with 5 deletions, 1 
duplication, and 1 missense point mutation. Other observed genetic alterations occurred in the 
c-kit exon 9 (23%) and c-kit exon 13 (8%), while 2 PT (15%) showed a c-kit and PDGFR 
wild type status. Similar results have also been described in previous publications (2, 9, 13-
14). 
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The fact that we could not detect any PDGFR mutations in our group of malignant GIST 
supports the assumption, that GISTs with this genetic alteration are associated with a lower 
malignant potential and therefore have a better prognosis (10, 14). 
The exon 11 alterations, which mostly occur in gastric GIST (5, 14), were also mostly 
detected in our PT of the stomach (4 of 7 cases). In 3 of these 4 cases, for which a clinical 
follow-up was available, a stable disease or no evidence of disease was observed, which is 
congruent with published data (12). No correlation between outcome and type of exon 11 
alterations could be seen. So the PT of patient D, who died of disease, had the same 
heterozygous exon 11 deletion (p.W557_K558) as Patient J, who showed no evidence of 
disease. Interestingly, both showed a switch to homozygosity in their metastatic tumours, 
which was described as a prognostically unfavourable factor (15). In addition the metastasis 
of patient D harboured a point mutation in exon 13. Previous studies showed, that exon 13 
alterations result in poor response to tyrosine kinase inhibitor therapy (16). This could be 
responsible for the more aggressive course of the disease of this patient, while receiving 
Imatinib and Sunitinib without any clinical or radiological response. It remains debatable, 
whether the genetic changes form PT to metastasis in these 2 cases, in which the here 
investigated metastatic tissue probes were taken after the start of the drug therapy, were a 
consequence of the administration of imatinib and/or sunitinib. The other 3 patients with exon 
11 alterations, who showed a stable disease or no evidence of disease, initially received 
Imatinib therapy. In one patient the therapy was stopped after the end of the adjuvant cycle (1 
year) with no evidence of residual disease. In another patient a change to Sunitinib was 
necessary due to liver toxicity. 
Exon 9 alterations generally seem to be associated with a worse course of disease. In our 
study all three observed cases showed the frequent p.502_503AY duplication (12, 17-19) 
heterozygously in PT and in metastases. The 2 patients with exon 9 mutations and PT in the 
small intestine showed a tumour progression under tyrosine kinase inhibitor therapy (Imatinib 
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and Sunitinib) and died of disease. One of these two patients (A) showed a tumour 
progression despite a dosage elevation of imatinib up to 600 mg/day. The third patient with 
exon 9 alteration, whose PT was located in the pancreas, shows stable disease under Sunitinib 
treatment after Imatinib therapy was stopped due to tumour progression and side effects. 
One of the two patients with wild type GIST was diagnosed only 6 month before the end of 
our observation period, so no reliable follow-up data is available. The other wild type patient 
died of disease, showing a rapid tumour progression during tyrosine kinase inhibitor treatment 
(Imatinib, Sunitinib). This poor response of wild type GIST patients was also repeatedly 
reported in literature (9, 11-12). 
In two patients (K and L) we detected novel exon 11 alterations so far not described: A 14 
amino acids deletion (p.E554_N567) in case K with heterozygosity in both PT and metastasis 
and a 12 amino acids duplication (p.P577_R588) in case L, being heterozygous in PT and 
homozygous in the metastasis. Unfortunately, no clinical follow-up was available. 
Until now only a few cases of GIST in the rectovaginal septum have been described in the 
English literature (20-29). In all these reports, similarly to our case, this localization seems to 
be associated with a favourable prognosis. In the few cases with reported genotyping (24-25), 
no c-kit exon 13 alteration – like in our case – was described. 
Taken together, our study, which is based on a population-based collective of metastatic 
GIST, confirms the observations of other researchers: GISTs with a malignant behaviour are 
mostly associated with genetic alterations in exons 9 and 11 of the c-kit gene or harbour wild-
type c-kit. PDGFR alterations on the other hand only rarely result in metastatic disease. 
In here described setting of a population-based observational study with a small number of 
cases with different, not standardized treatment modalities, it remains difficult, to draw certain 
conclusions for a possible relation between the genetic alterations of c-kit and PDGFR in PT 
and metastases, respectively, and the response to tyrosine kinase inhibitor therapy. In 
tendency, our observations support the results of previous studies, in that GISTs with a wild 
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type genotype or a c-kit exon 9 alteration in primary tumour or a secondary mutation in 
metastasis show a worse response to Imatinib or Sunitinib treatment than other c-kit 
alterations. But, especially in patients with exon 9 mutations and treatment with elevated 
doses of imatinib according to the results of the MetaGIST group (30), further studies with a 
larger number of patients with metastasized GIST are needed to confirm these findings. 
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Table 1 Used PCR-primer for c-kit and pdgfr-  
EXON Primer sequence 5’ -> 3’ 
c-kit exon 8 forward TTCTGCCCTTTGAACTTGCT 
c-kit exon 8 reverse AATTGCAGTCCTTCCCCTCT 
c-kit exon 9 forward TCCTAGAGTAAGCCAGGGCTT 
c-kit exon 9 reverse CAGAGCCTAAACATCCCCTTA 
c-kit exon 11 forward CCAGAGTGCTCTAATGACTGA 
c-kit exon 11 reverse CCTTAAAGTCACTGTTATGTGTACC 
c-kit exon 12 forward GGTTTGCCATAGAGAACATCG 
c-kit exon 12 reverse CAAAAAGCACAACTGGCAAA 
c-kit exon 13 forward TCCTGTATGGTACTGCATGC 
c-kit exon 13 reverse AAAGGCAGCTTGGACACGGCT 
c-kit exon 14 forward TGGGAGGCAGAATTAATCT 
c-kit exon 14 reverse AACCCTTATGACCCCATGAA 
c-kit exon 15 forward GACCCATGAGTGCCCTTCTA 
c-kit exon 15 reverse TTGACCATTGGCACTGCTAC 
c-kit exon 16 forward GCCACTGTCTTTTCCTTTCC 
c-kit exon 16 reverse TGGCTCTAAAATGCTCTGTTCTC 
c-kit exon 17 forward TGTATTCACAGAGACTTGGC 
c-kit exon 17 reverse GCAGGACTGTCAAGCAGAGA 
c-kit exon 18 forward CATTTCAGCAACAGCAGCAT 
c-kit exon 18 reverse CAAGGAAGCAGGACACCAAT 
pdgfr- exon 10 forward TCCACTCATTGCCATGACTC 
pdgfr- exon 10 reverse AGATGCGGCTCAGCTGATGA 
pdgfr- exon 12 forward GGTGCACTGGGACTTTGGTAATTCAC 
pdgfr- exon 12 reverse CAAGGGAAAAGGGAGTCTTGGAG 
pdgfr- exon 14 forward GAGAACAGGAAGATGGTAGCTCA 
pdgfr- exon 14 reverse TTCACAACCACATGTGTCCA 
pdgfr- exon 18 forward CCAGTCTTGCAGGGGTGATGCTAT 
pdgfr- exon 18 reverse AACAGGCACCGAATCTCTAGAAGC 
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Table 2 Patients' and tumour characteristics 
Patient 
ID Sex 
age 
(years) 
Site primary 
tumor (PT) 
PT 
diameter 
(cm) 
PT mitoses 
(per 50 hpf) 
PT 
histology Mutation PT 
Site of metastasis 
(M) Mutation M 
Observation 
period 
(months) 
Progression 
free survival 
(months) 
Time 
spread 
PT - M 
(months) 
State 
of 
disease 
Duration (months) 
and dosage 
Imatinib-therapy 
Withdrawel 
Imatinib 
therapy 
(reason) 
Duration 
(months) and 
dosage Sunitinib 
therapy 
Withdrawel 
Sunitinib- 
therapy 
(reason) 
A m 71 small intestine 9 22 S 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
peritoneum 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
93 23 23 DOD 38 (400mg/day)  25 (600mg/day) Yes (TP) 1 (50mg/day) Yes (SE) 
B f 68 jejunum 8 4 S 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
mesenterium 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
47 19 19 DOD 3 (400mg/day) Yes (TP, SE) No  
C f 31 stomach 21 21 S none peritoneum none 52 20 20 DOD 
1 (400mg/day before 
PT surgery 
4 (800mg/day after 
metastasis) 
Yes (TP) 1 (37.5 mg/day) Yes (SE) 
D m 64 stomach 23 8 S 
c-kit exon 11 
(p.W557_K558del) 
heterozygous 
retroperitoneum 
c-kit exon 11 
(p.W557_K558del) 
homozygous; 
c-kit exon 13 
(p.V654A) 
heterozygous 
79 17 78 DOD 28 (400mg/day) Yes (TP) 30 (37.5 mg/day) Yes (TP) 
E f 72 septum rectovaginale 
n/a 
(biopsy) 1 S 
c-kit exon 13 
(p.K642E) 
heterozygous 
septum rectovaginale c-kit exon 13 (p.K642E) heterozygous 180 114 114 SD 
20 (400mg/day) 
1 (800mg/day) Yes (SE) No  
F f 66 pancreas 4 2 S 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
liver, omentum 
c-kit exon 9 
(p.502_503dupAY) 
heterozygous 
168 104 104 SD 38 (400mg/day) 3 (800mg/day) Yes (TP, SE) 12 (37.5 mg/day) No 
G f 65 stomach 8 24 S 
c-kit exon 11 
(p.K558_E562del) 
heterozygous 
liver  
c-kit exon 11 
(p.K558_E562del) 
heterozygous 
41 11 11 SD 18 (400mg/day) No No  
H f 68 stomach 11 4 S none liver, lymph node none 6 6 0 NED 4 (400mg/day) Yes (SE) No  
I f 68 jejunum 8 40 S 
c-kit exon 11 
(p.W557G) 
heterozygous 
omentum, 
peritoneum 
c-kit exon 11 
(p.W557G) 
heterozygous 
35 22 22 NED 1 (400mg/day) Yes (SE) 9 (50 mg/day) No 
J m 65 stomach 10 40 S 
c-kit exon 11 
(p.W557_K558del) 
heterozygous 
liver 
c-kit exon 11 
(p.W557_K558del) 
homozygous 
26 24 24 NED 
12 (400mg/day after 
PT) 
1 (400mg/day after 
metastasis) 
No  No  
K m 55 stomach 7.5 100 S/E 
c-kit exon 11 
(p.E554_N567del) 
heterozygous 
liver 
c-kit exon 11 
(p.E554_N567del) 
heterozygous 
n/a n/a 0 n/a n/a n/a n/a n/a 
L f 74 lig. gastrocolicum 25 6 S/E 
c-kit exon 11 
(p.P577_R588dup1
2) heterozygous 
liver, bone 
c-kit exon 11 
(p.P577_R588dup12) 
homozygous 
n/a n/a 25 n/a n/a n/a n/a n/a 
M m 80 small intestine 15 7 E 
c-kit exon 11 
(p.V559_G565del) 
heterozygous 
omentum, 
peritoneum 
c-kit exon 11 
(p.V559_G565del) 
Heterozygous 
n/a n/a 0 n/a n/a n/a n/a n/a 
Sex (m=male; f=female); PT histology (S=spindle cellular; E=epitheloid); state of disease (DOD=death of disease; SD= stable disease; NED= no evidence of disease); n/a= not available; TP= tumour progression; SE= side effects 
